Saracatinib SRC Inhibitors
Chemical Information
|
Product name:Saracatinib |
Purity:98% min |
|
CAS NO:379231-04-6 |
Solubility:DMSO : ≥ 32 mg/mL (59.04 mM) |
|
Molecular Formula:C27H32ClN5O5 |
Package:Package according to customer requirements |
|
Molecular Weight:542.026 |
Storage:Store at -20℃ |
Remarks
Saracatinib, also known as AZD0530, is an orally available dual-specific inhibitor of Src and Abl with anti-invasive and anti-tumor activities. Src and Abl are protein tyrosine kinases that are overexpressed in chronic myeloid leukemia cells. Saracatinib binds to and inhibits these tyrosine kinases and their effects on cell motility, cell migration, adhesion, invasion, proliferation, differentiation, and survival.
Related Products:
Afatinib dimaleate; Neratinib; Bosutinib; Bosutinib Intermediates; Bosutinib Monohydrate; Dasatinib; NVP-BHG712; PP1; PP2; A-966492; G007-LK; SU6656; Tirbanibulin; TPX-0005; Afatinib
References
[1]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261.
[2]. Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.